Centaurus Financial, Inc. Regeneron Pharmaceuticals, Inc. Transaction History

Centaurus Financial, Inc.

$1.44 Billion
Q3 2024

A detailed history of Centaurus Financial, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Centaurus Financial, Inc. holds 120 shares of REGN stock, worth $90,026. This represents 0.01% of its overall portfolio holdings.

Number of Shares

120

Previous 112 7.14%

Holding current value

$90,026

Previous $117,000 7.69%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1024.09 - $1201.76 $8,192 - $9,614	8 Added 7.14%	120 $126,000
Q2 2024 Sep 20, 2024	BUY	$883.2 - $1071.19 $98,918 - $119,973	112 New	112 $117,000
Q4 2023 Feb 26, 2024	SELL	$775.18 - $881.7 $37,208 - $42,321	-48 Reduced 29.09%	117 $102,000
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $114,254 - $139,321	165 New	165 $136,000
Q3 2022 Dec 05, 2022	BUY	$573.97 - $724.32 $2,869 - $3,621	5 Added 0.24%	2,112 $1.46 Million
Q2 2022 Aug 02, 2022	BUY	$548.35 - $738.84 $548 - $738	1 Added 0.05%	2,107 $1.25 Million
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $13,092 - $15,365	22 Added 1.06%	2,106 $1.47 Million
Q4 2021 Feb 01, 2022	BUY	$543.48 - $670.97 $371,740 - $458,943	684 Added 48.86%	2,084 $1.32 Million
Q3 2021 Nov 12, 2021	BUY	$574.03 - $680.96 $9,184 - $10,895	16 Added 1.16%	1,400 $847,000
Q2 2021 Aug 10, 2021	BUY	$472.8 - $558.54 $654,355 - $773,019	1,384 New	1,384 $773,000
Q2 2019 Aug 15, 2019	SELL	$299.6 - $414.82 $68,908 - $95,408	-230 Closed	0 $0
Q1 2019 Jul 01, 2019	SELL	$372.08 - $439.57 $122,414 - $144,618	-329 Reduced 58.86%	230 $559,000
Q1 2019 May 13, 2019	BUY	$372.08 - $439.57 $207,992 - $245,719	559 New	559 $230,000

Others Institutions Holding REGN

# of Institutions

1,532

Shares Held

83.8M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $80.4B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Centaurus Financial, Inc. with notifications on news.

Account

Centaurus Financial, Inc. Regeneron Pharmaceuticals, Inc. Transaction History